Patents by Inventor John Michael McCall

John Michael McCall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sepiapterin reductase inhibitors
    Patent number: 9963462
    Abstract: Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: May 8, 2018
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Mark Joseph Tebbe, Holly Victoria Atton, Craig Avery, Steven Mark Bromidge, Mark Kerry, Adrian Kotei Kotey, Nathaniel J. Monck, Mirco Meniconi, Mark Peter Ridgill, Heather Tye, Eddine Saiah, Kai Peter Johnsson, Katarzyna Irena Gorska, Hairuo Peng, John Michael McCall
  • SEPIAPTERIN REDUCTASE INHIBITORS
    Publication number: 20170096435
    Abstract: Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 6, 2017
    Inventors: Mark Joseph Tebbe, Holly Victoria Atton, Craig Avery, Steven Mark Bromidge, Mark Kerry, Adrian Kotei Kotey, Nathaniel J. Monck, Mirco Meniconi, Mark Peter Ridgill, Heather Tye, Eddine Saiah, Kai Peter Johnsson, Katarzyna Irena Gorska, Hairuo Peng, John Michael McCall
  • Treatments for nervous disorders
    Publication number: 20030232829
    Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Application
    Filed: April 28, 2003
    Publication date: December 18, 2003
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • Treatments for nervous disorders
    Patent number: 6586427
    Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: July 1, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • Reboxetine for treatment obsessive compulsive disorders and panic disorder
    Patent number: 6391876
    Abstract: This invention relates to the use of reboxetine in the treatment of Obsessive Compulsive Disorders and Panic Disorders.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: May 21, 2002
    Assignee: Pharmacia and Upjohn Company
    Inventors: Adriana Dubini, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • New treatments for nervous disorders
    Publication number: 20020049230
    Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Application
    Filed: August 13, 2001
    Publication date: April 25, 2002
    Applicant: Pharmacia & Upjohn Company
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • Treatments for nervous disorders
    Patent number: 6352986
    Abstract: This patent application describes the treatment of Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: March 5, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong